ArticleAlimentary pharmacology & therapeutics2026
Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis.Alimentary pharmacology & therapeutics · 2026Article
- Editorial on 'Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis'.Alimentary pharmacology & therapeutics · 2026Article
- Editorial on: 'Lowering the C-Reactive Protein Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis'. Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReal-world data demonstrate that patients hospitalised with non-acute severe UC (NASUC) experience intravenous corticosteroid (IVCS) failure rates approaching those of ASUC, yet no dedicated management guidelines exist.
aimsWe aimed to determine whether inpatient medical therapy and colectomy risk differ between TWC-positive ASUC, compared to hospitalised patients who did not meet TWC (NASUC), and evaluate if a reduced CRP threshold (≥ 12 mg/L) improves case capture of high-risk patients.
methodsWe analysed 503 consecutive acute UC admissions to a tertiary IBD centre (2015-2024). Patients not meeting TWC for ASUC were classified as NASUC. Propensity score matching (PSM) compared colectomy risk between ASUC and NASUC after adjustment for gender, endoscopic severity, disease extent and therapy on admission.
resultsA total of 145 (29%) acute UC admissions did not meet TWC for ASUC. The predominant NASUC phenotype was stool frequency ≥ 6/24 h without systemic toxicity (77%). Lowering the CRP threshold to ≥ 12 mg/L would have reclassified 26% of NASUC patients as ASUC, capturing 43% (6/14) of patients who required colectomy within 1-year. After PSM, there was no significant difference in colectomy between ASUC and NASUC at 30-days (9% vs. 5%, p = 0.367), 90-days (11% vs. 5%, p = 0.158) or 1-year (18% vs. 13%, p = 0.479) and until last follow-up (p = 0.77).
conclusionNASUC is not a benign clinical entity. Colectomy risk were comparable between ASUC and NASUC inpatients when matched for objective disease severity and treatment exposure. A reduced CRP threshold (≥ 12 mg/L) improves identification of high-risk patients currently missed by the standard TWC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.